GEMCRO GEM MODEL CATALOG
Precision CRISPR-engineered mouse models
Immunodeficiency · Cancer · Neurodegeneration · Metabolic Disease · Infection · Antibody PK
GEMCRO provides CRISPR/Cas9-engineered and disease-relevant mouse models produced through cryobanked sperm or embryos, IVF expansion, genotyping, and study-oriented cohort planning.
|
|
|
|
WHY SOURCE FROM GEMCRO
Built by the same team that runs the studies.
01
In-house CRISPR/Cas9
Gene editing, breeding, and characterization are managed at GEMCRO's R&D center. |
02
Catalog to custom
If the model is not listed, custom CRISPR design can be scoped from the biological objective. |
03
Cryobanked for speed
Frozen sperm or embryos enable IVF-based production after order confirmation. |
04
Scaled cohorts
IVF expansion supports age-matched cohorts for nonclinical research. |
|
|
HOW IT WORKS
From inquiry to a genotyped cohort.
① Confirm model
Model, strain, genotype, sex, age, quantity, and timeline. |
② IVF production
Cryopreserved sperm or embryos are used for cohort production. |
③ Genotyping
Offspring are PCR-genotyped and raised to the agreed age. |
④ Delivery
Typical production timeline: approximately 2–3 months after confirmation. |
| OVERSEAS OPTION |
Cryopreserved sperm or embryos can be shipped for institutions equipped for IVF or embryo transfer.
This may reduce live-animal import burden and allow local cohort production. |
|
|
MODEL CATALOG
Models organized by disease area.
KO = Knockout · KI = Knock-in · Tg = Transgenic · cKO = Conditional knockout
01 / Immunodeficiency Models
Engraftment and humanized-immune-system backgrounds |
02 / Cancer Models
Oncogene, tumor-suppressor and patient-mutation models |
| Model |
Type |
Background |
Expression |
Reference |
ApcL850X
ApcMin mutation intestinal tumor model |
KI |
C57BL/6 |
Endogenous |
On request |
ApcI716X
Apc truncation-based intestinal tumor model |
KI |
C57BL/6 |
Endogenous |
On request |
Tg(pCAG-LSL-EML4-ALK); Tg(SPC-CreERT2)
Inducible EML4-ALK lung cancer model |
Tg |
C57BL/6 |
Lung-specific |
Pyo et al., 2017 |
Trp53null
p53-deficient tumor model |
KO |
C57BL/6 |
Whole-body |
Yun et al., 2021 |
Trp53null
p53-deficient tumor model |
KO |
FVB |
Whole-body |
Yun et al., 2021 |
Trp53R172H
Human p53 R175H-equivalent hotspot mutation |
KI |
C57BL/6 |
Endogenous |
On request |
03 / Neurodegenerative & Dementia Models
Amyloid, tau and alpha-synuclein pathology |
| Model | Type | Background | Expression | Reference |
|---|
Tg(NSE-hAPPsw)
Human APP, Swedish mutation | Tg | C57BL/6 | Brain | Son et al., 2018 |
Tg(NSE-hTau23)
Human Tau | Tg | C57BL/6 | Brain | Data sheet |
Tg(NSE-hαSyn)
Human alpha-synuclein | Tg | C57BL/6 | Brain | Lee et al., 2022 |
ApoeAPOE4
Humanized APOE4 model | KI | C57BL/6 | Endogenous | On request |
04 / Metabolic Disease Models
Obesity, diabetes, MASH and MAFLD |
| Model | Type | Background | Expression | Reference |
|---|
Lepnull
Leptin-deficient Ob model | KO | C57BL/6 | Whole-body | Kim et al., 2022 |
Leprnull
LepR-deficient Db model | KO | C57BL/6 | Whole-body | Lee et al., 2025 |
Pnpla3I148M
MAFLD risk model | KI | C57BL/6 | Endogenous | On request |
PpargS273A
Insulin-sensitizing metabolic model | KI | C57BL/6 | Endogenous | On request |
05 / Cardiovascular & Lipid Metabolism Models
Atherosclerosis, vascular inflammation, dyslipidemia and cardiac remodeling |
| Model | Type | Background | Expression | Reference |
|---|
Apoenull
Hyperlipidemia/atherosclerosis model | KO | C57BL/6 | Whole-body | On request |
Ldlrnull
Diet-accelerated atherosclerosis model | KO | C57BL/6 | Whole-body | On request |
Agernull
Vascular and metabolic inflammation model | KO | C57BL/6 | Whole-body | On request |
Tg(Ager); Tg(Tie2-CreERT2); Apoenull
Endothelial-specific atherosclerosis model | Tg | C57BL/6 | Endothelial-specific | On request |
Psmb8/Psmb9 DKO
Immunoproteasome-deficient model | KO | C57BL/6 | Whole-body | Lim et al., 2021 |
Adora2bD296G
Cardioprotective variant model | KI | C57BL/6 | Endogenous | Lim et al., 2019 |
06 / Infection & Interferon Response Models
Humanized viral receptors and interferon-pathway models |
| Model | Type | Background | Expression | Reference |
|---|
Ace2em1(ACE2)Gmcr — hiACE2
Humanized ACE2 viral infection model | KI | C57BL/6 | Endogenous | Park et al., 2024 |
Ifnarnull
IFN-alpha receptor KO viral infection model | KO | C57BL/6 | Whole-body | On request |
Ifngrnull
IFN-gamma receptor KO host-defense model | KO | C57BL/6 | Whole-body | On request |
07 / Antibody PK & Fc Biology Models
Human FcRn-mediated antibody recycling and translational PK |
| Model | Type | Background | Expression | Reference |
|---|
Fcgrtem1(FCGRT)Gmcr — hiFcRn
Humanized FcRn antibody PK model | KI | C57BL/6 | Endogenous | Lee et al., 2025 |
08 / Complement, Innate Immunity & Immune Checkpoint Models
Complement pathway, phagocytosis and innate immune regulation |
| Model | Type | Background | Expression | Reference |
|---|
C1qanull
Lupus-like autoimmunity model | KO | C57BL/6 | Whole-body | Kim et al., 2021 |
C3null
Complement-deficient host-defense model | KO | C57BL/6 | Whole-body | Choi et al., 2022 |
Cd47null
Don't-eat-me signal-deficient model | KO | C57BL/6 | Whole-body | Kim et al., 2018 |
Il2ranull
CD25/Treg-related inflammation model | KO | C57BL/6 | Whole-body | On request |
Il2ranull
CD25/Treg-related inflammation model | KO | FVB | Whole-body | On request |
09 / Aging & Degeneration Models
Progeroid aging, laminopathy and retinal degeneration |
| Model | Type | Background | Expression | Reference |
|---|
LmnaG609G
Progeroid laminopathy/accelerated-aging model | KI | C57BL/6 | Endogenous | On request |
Zmpste24flox
Conditional progeroid aging model | cKO | C57BL/6 | Conditional | On request |
Pde6bR560C
rd10 retinal degeneration model | KI | C57BL/6 | Endogenous | Cha et al., 2022 |
|
|
Need a model not listed here?
Custom KO, KI, cKO, point mutation, reporter/tag, humanized allele, large deletion, locus replacement and strain-crossing projects can be discussed.
|
|
GEMCRO Inc.
Rm. 730, GL Metro City, 201 Hyangdong-ro, Deogyang-gu, Goyang-si, Gyeonggi-do 10545, Republic of Korea
+82-2-6677-6649 · contact@gemcro.com |
|
|
|